ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AGY Allergy Therapeutics Plc

3.00
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics Plc LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.00 2.80 3.20 3.00 3.00 3.00 120,404 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 59.59M -43.07M -0.0090 -3.33 142.99M
Allergy Therapeutics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AGY. The last closing price for Allergy Therapeutics was 3p. Over the last year, Allergy Therapeutics shares have traded in a share price range of 0.85p to 3.80p.

Allergy Therapeutics currently has 4,766,439,938 shares in issue. The market capitalisation of Allergy Therapeutics is £142.99 million. Allergy Therapeutics has a price to earnings ratio (PE ratio) of -3.33.

Allergy Therapeutics Share Discussion Threads

Showing 4976 to 4998 of 5000 messages
Chat Pages: 200  199  198  197  196  195  194  193  192  191  190  189  Older
DateSubjectAuthorDiscuss
27/3/2024
07:53
Fingers crossed, exciting times at last. (impo)

"The Group expects to be the first company to register SCIT Grass immunotherapy under the Therapie Allergene Verordnung (TAV) programme".

Preparations are also ongoing for the initiation of the G308 combined short-term and long-term paediatric clinical trial that is due to commence in Q2 2024. This trial is designed to support a paediatric indication for the Group's Grass MATA MPL product and to also provide long-term efficacy and ................."disease modifying" data.......................................................This trial will meet the previously communicated requirements of Paediatric Committee for a paediatric registration in Germany.

jimmyloser
26/3/2024
17:52
CoinOdd movement today. Do you have any thoughts?ThanksJimmy
jimmyloser
22/3/2024
11:08
Farmer George,
I obviously can’t say what others views are but I am tentatively optimistic and hope that my optimism will be proved to not be misplaced within the next ten days and possibly as soon as next week!
As I have posted on numerous occasions I believe the potential here is huge!



Impo

jimmyloser
20/3/2024
22:10
Are we optimistic about the outlook for AGY - been out of the loop for a while.
farmergeorge
20/3/2024
21:39
I’m sorry, it wasn’t meant as a criticism. Someone’s been trying to buy in bulk at just below the mid-price for over a week.
coinbase
20/3/2024
21:21
CoinI said... appearJimmyI don't have level 2Thanks
jimmyloser
20/3/2024
21:15
Jimmyloser, I don’t agree with you. Our ‘friends’; at Panmure bought 754,373 shares at an average of 2.63151 GBX (£19,851.41) and sold 880,000 shares at an average of 2.72 GBX (£23,936). Keep half an eye on the bid tomorrow morning.
coinbase
20/3/2024
15:32
What a rum day, mm's appear to have bought over 1million and as yet, with no impact on the bid or offer at 15.32hrs.

Coin, any thought?

jimmyloser
15/3/2024
13:55
Thanks Coin.
jimmyloser
15/3/2024
10:23
Jimmyloser, they’ll know EVERYTHING post phase 1. Think of it as all 3 phases rolled into 1.
coinbase
15/3/2024
06:17
G306 is the study that ends the series of failures that began with the first study, on grasses, which failed the registration process already in 2009. G301, 4 injections promised an improvement of about 20% in symptoms. Although significant, this improvement has been judged inadequate by regulatory bodies as it is not so important if the improvement is demonstrated, but if this improvement, combined with a strong tolerability profile, brings a strong innovation compared to treatments already available and already registered. And that's exactly the point. The G306 study, which came after 5 unsuccessful attempts, seems to show (it seems because nothing is transparent and much is instead opaque) that the improvement in symptoms is significant although it is not known by how much (strange, no??) and this improvement is combined with a "acceptable" tolerability. "Acceptable" is too partial a judgment and together with the opacity regarding the degree of symptomatic improvement obtained, it casts serious doubt on whether the product is approved. Last potentially tragicomic aspect. It is unclear how many injections were administered in the G306 study. The product currently on the market and currently promoted requires 4 injections. If the number of injections in the G306 study were greater than 4, I leave it to you to imagine the reaction of the medical profession to such news. Stay away from the management of this company.
beccasan
14/3/2024
18:59
CoinI love your positive outlook but what do the initials mean?ThanksPS: I dream of a third of that figure
jimmyloser
14/3/2024
17:42
21 GBX by Christmas. #MicDrop
coinbase
13/3/2024
15:22
Maybe an 8p bid will do it
jpuff
13/3/2024
13:50
Jimmy I gather you are a good taster as you are able to measure acidity. You and your alter ego, the CEO, have the same followers, same results, same attitude.
beccasan
13/3/2024
13:14
Vergeltung,
I do like your thought provoking and reasoned posts, rather less acidic than your alter ego, beccasan.

1) You do seem rather keen on bashing management at every opportunity. I actually believe that they are doing a sound job and there can be zero doubt that they simply would not be there if they weren't. Yes, I know about the issues regarding quality systems etc. (Let me add that I will be personally happier when I see management awarded share options !)
impo, you need have no fear regarding the commercialisation of the products when we have two major shareholders now in the driving seat. Expect news circa 2/4 weeks on that front.
2)We have a long way to run before we are at the stage of G306 and above all right now the news on safety was really welcome.
Finally, agreed, but lets hope that they play fair. They certainly have up until now impo.

jimmyloser
13/3/2024
12:31
Coinbase, Jimmy, I am as keen as any of you that AGY should finally escape its period of bad luck (partly caused by atrocious management - but that's a different matter, one Skygem surely must be asking themselves about) and notch up a few clinical achievements. I also agree that the news from the clinic has been good. However:
1) I am underwhelmed at the reaction to the success of G306 announced in November (! 4 months ago!!)- which should occasion the start of final MA approvals and possibly of licensing / M&A activity; it raises questions about management competence that nothing seems afoot at all on this, a target the company has been aiming at since its foundation and
2) this recent Peanut announcement - extremely limited exposure with primarily safety objectives and some blood-chemistry. Highly promising though it is, it's all super-preliminary and represents the very start of the process that G306 supposedly represented the end of.
I agree with you that there is great upside potential here but weighing on this are a) the issue of rudimentary management competence and b) the future financing needs which might turn out badly for us minor shareholders after resolutions 11-14 passed at the AGM.

vergeltung
13/3/2024
11:45
Coin
We are aligned. Yesterdays news on tolerability and using biomarkers was very reassuring.

Commercialisation news is what the market needs as does Skygem :-)

jimmyloser
13/3/2024
11:34
Jimmyloser, we’ll know one way or another by the end of the month. If they don’t kill anyone and the EMA look kindly on them then it’ll explode.
coinbase
13/3/2024
10:17
I came across this and to me it was an eye opener and shows a small sample of the brains involved and people developing this much needed product.

A product for peanut allergic reaction is much needed but the market I would suggest for food allergic reaction must surely be a much bigger prize commercially. However, the news that should see this start to move (impo) is the response from the likes of the FDA.

Whilst I have skin in AGY's succesful transformation and keep an eye on it, I'll wager that huge corporation's are all watching even closer.....again impo.

Fingers firmly crossed. DYOR ETC

jimmyloser
12/3/2024
09:25
“First patient receives subcutaneous dosing with no safety signals observed” says it all.
coinbase
12/3/2024
07:42
Allergy Therapeutics commences subcutaneous dosing in peanut allergic patients in Phase I/IIa VLP Peanut PROTECT Trial - hXXps://www.londonstockexchange.com/news-article/AGY/vlp-peanut-protect-trial-update/16372281
coinbase
11/3/2024
16:57
?Read the runes :
jimmyloser
Chat Pages: 200  199  198  197  196  195  194  193  192  191  190  189  Older

Your Recent History

Delayed Upgrade Clock